Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafoxiparin for Cervical Ripening in Term Pregnant Women
NCT04000438Phase 2Completed
- Sponsor
- Dilafor AB
- Start
- Jun 2019
- Primary completion
- Feb 2023
- Modality
- Bivalent/Multivalent Binders
- Countries
- 2
01
Overview
A Phase 2 trial of tafoxiparin in unfavorable cervix, sponsored by Dilafor AB. Started Jun 2019; status: completed.
02
Drugs
tafoxiparin
03
Conditions
unfavorable cervix
Beyond the preview
Go deeper on NCT04000438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04000438.